QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA ®

27 April 2020 Australian life sciences company, QBiotics Group Limited (QBiotics) has commercialised the first product for its lead compound, tigilanol tiglate, with the launch of STELFONTA ® in the European markets at the Virbac Oncology Summit Webinar Event (24 April 2020). STELFONTA ® (tigilanol tiglate) is now available as the first pharmaceutical treatment for all grades of canine non-metastatic mast cell tumours (MCT). 1 MCTs are the second most frequent cancer diagnosed in dogs and the most common skin cancer, accounting for up to 21% of skin cancer cases. 2 Read the full media release QBiotics Group Ltd., Data on file. 2020. Garrett, LD. 2014. Canine mast cell tumors: diagnosis, treatment, and prognosis. Veterinary Medicine: Research and Reports, Vol 5.

The release as fetched from its publisher. qbiotics.com ↗